Search

everythinglearnresearchcommunity

for

Search:↓

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

Male pattern baldness might have evolved to help protect against prostate cancer by increasing UV radiation on the scalp.

Computational methods help design drugs targeting prostate cancer proteins.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.

Targeting FGF5 could help treat prostate cancer.

A prostate cancer drug can lower the levels of a protein that the coronavirus uses to enter lung cells.

Researchers found four natural compounds that can change DHT levels in prostate cancer cells.

Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.

Certain gene combinations may affect prostate cancer risk, and GSTP1 methylation is linked to tumor aggressiveness.

Male pattern baldness does not cause an increased risk of prostate cancer.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Early baldness and little chest hair may indicate higher prostate cancer risk.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.

Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.

The role of 5α-reductase-3 in prostate cancer is unclear and needs more research.

There might be a link between male pattern baldness and a higher risk of prostate cancer and testicular cancer.

Early-onset male baldness may indicate a higher risk of prostate cancer.

Early baldness in men may indicate a higher risk of prostate cancer.